About 15,140 results

ALLMedicine™ Neuroblastoma Center

Research & Reviews  5,264 results

Systematic evaluation of membrane-camouflaged nanoparticles in neutralizing Clostridium...
Journal of Nanobiotechnology; Xu J, Li D et. al.

Mar 19th, 2023 - Clostridium perfringens ε-toxin (ETX) is the main toxin leading to enterotoxemia of sheep and goats and is classified as a potential biological weapon. In addition, no effective treatment drug is currently available in clinical practice for this t...

Stent-Graft Placement for Radiation-Induced Abdominal Aortic Stenosis after Renal Autot...
International Heart Journal; Ono R, Watanabe M et. al.

Mar 18th, 2023 - Renovascular hypertension (RVH) is a common cause of secondary hypertension. However, there have been no reports on RVH due to radiation-induced abdominal aorta stenosis after renal autotransplantation. A 27-year-old woman with a history of neurob...

Top 10 Nested Pattern Head and Neck Lesions to Notice.
Head and Neck Pathology; Lott Limbach A, Chute DJ

Mar 18th, 2023 - Nested is defined as "cellular clusters arranged in small groupings with intervening vascular or stromal networks, lacking lumens or glandular formation." Using this definition, multiple neoplastic and non-neoplastic lesions of the head and neck c...

Synchronous Hepatoblastoma and Neuroblastoma in Two Chinese Infants.
Fetal and Pediatric Pathology; Shao B, Wang YZ et. al.

Mar 18th, 2023 - Background: Commonly, pediatric solid tumors occur independently. Only two patients with synchronous hepatoblastoma (HBL) and neuroblastoma (NBL) have been reported. Case reports: Two Chinese infants presented with abdominal mass at 10 and 8 month...

Secondary Lung Tumors

Mar 16th, 2023 - Practice Essentials Secondary lung tumors are neoplasms that spread from a primary lesion. The primary tumor can arise within the lung or outside the lung, with the metastases traveling through the bloodstream or lymphatic system or by direct exte...

see more →

Guidelines  1 results

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marro...
British Journal of Cancer; Beiske K, Burchill SA et. al.

Apr 30th, 2009 - Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task...

see more →

Drugs  53 results see all →

Clinicaltrials.gov  445 results

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma

Mar 10th, 2023 - High risk neuroblastoma is an aggressive and lethal pediatric solid tumor. Survival remains less than 50% and those patients who do survive suffer many treatment-related acute and chronic toxicities, stressing a critical need for novel tumor-targe...

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Mar 9th, 2023 - 9-ING-41 is a first-in-class, intravenously administered, maleimide-based, small molecule, potent selective GSK-3β inhibitor with significant pre-clinical and clinical anticancer activity. In the ongoing Actuate 1801 study in a cohort of over 90 p...

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Mar 9th, 2023 - One 131I-omburtamab treatment cycle takes 4 weeks and includes a treatment dose, and an observation period and post-treatment evaluations. One 131I-omburtamab treatment cycle for Japan only takes 5 weeks and includes a dosimetry dose (2mCi) of 131...

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Mar 9th, 2023 - PRIMARY OBJECTIVE: I. To determine whether administration of eflornithine hydrochloride (eflornithine [DFMO]) in combination with dinutuximab, irinotecan hydrochloride (irinotecan) and temozolomide results in an improved response rate compared to ...

9-ING-41 in Patients With Advanced Cancers

Mar 9th, 2023 - 9-ING-41 is a first-in-class, intravenously administered, maleimide-based small molecule potent selective GSK-3β inhibitor with significant pre-clinical antitumor activity. GSK-3 is a serine/threonine kinase initially described as a key regulator ...

see more →

News  277 results

Another Approval Bites the Dust; Booze-Cancer Link Off Radar; Lung Ca Surveillance

Dec 2nd, 2022 - Roche/Genentech will voluntarily withdraw accelerated approval of atezolizumab (Tecentriq) for advanced bladder cancer. The move follows the failure of a phase III trial to show a benefit in overall survival. Cryotherapy proved more effective than...

FDA Declines to Approve Y-mAbs's Pediatric Cancer Drug

Dec 2nd, 2022 - (Reuters) - The U.S. health regulator on Thursday declined to approve a treatment from Y-mAbs Therapeutics for a rare form of nerve cancer in pediatric patients, dragging the company's shares down 16% in extended trading. Y-mAbs said it is assessi...

FDA Panel Votes Against Omburtamab for Rare Pediatric Cancer

Oct 31st, 2022 - Y-mAbs Therapeutics has suffered a setback in its efforts to win US approval for I-omburtamab to treat a rare pediatric cancer. On October 28, a Food and Drug Administration (FDA) advisory panel found a lack of evidence to support the drug's appro...

FDA Panel: All Thumbs Down for Antibody to Treat Metastatic Neuroblastoma

Oct 28th, 2022 - An FDA advisory committee voted unanimously against recommending approval of the radiolabeled monoclonal antibody 131I-omburtamab for progressive neuroblastoma with central nervous system (CNS)/leptomeningeal metastases. Citing perceived shortcomi...

FDA Raises Questions About BLA for Omburtamab in Pediatric Metastatic Neuroblastoma

Oct 27th, 2022 - The FDA has expressed concern about the efficacy of 131I-omburtamab prior to a meeting of the regulatory agency’s Oncologic Drugs Advisory Committee (ODAC) to examine data supporting the biologic license application (BLA) seeking the agent’s appro...

see more →

Patient Education  16 results see all →